For decades, the tricuspid valve—often colloquially referred to as the "forgotten valve" of the human heart—has been a source of frustration for cardiologists. While mitral and aortic valve interventions have long been standard practice, managing severe tricuspid regurgitation (TR) remained a clinical dead end, often relegated to conservative medical management that offered little more than symptom relief.
That narrative underwent a seismic shift at the European Society of Cardiology (ESC) Congress in Munich, Germany, where researchers unveiled the results of the TRIC-I-HF trial. Published simultaneously in the New England Journal of Medicine, the trial provides the strongest evidence to date that transcatheter tricuspid valve repair (TTVR) does more than just make patients feel better—it saves lives and keeps them out of the hospital.
The Core Findings: Beyond Quality of Life
The TRIC-I-HF trial represents a milestone in cardiovascular medicine. Lead investigator Jörg Hausleiter, MD, of Ludwig-Maximilians-Universität München, presented data demonstrating that for patients with symptomatic severe TR who are at high risk for heart failure (HF) events, transcatheter repair is significantly superior to medical therapy alone.
The primary results were striking. When assessing a composite of all-cause mortality and heart failure hospitalization at one year, the trial reported a win ratio of 2.42 (95% CI 1.76-3.33). This metric, which integrates both clinical outcomes and quality-of-life assessments, indicates a clear, statistically significant benefit to the intervention.
Even when stripping away the subjective quality-of-life improvements and focusing exclusively on hard clinical endpoints, the data remained robust. At three years, the combined risk of death or hospitalization for heart failure was 52.4% in the medical therapy group compared to just 21.0% in the intervention group (hazard ratio 0.40; 95% CI 0.29-0.55).
Perhaps most impressive to clinicians was the "number needed to treat" (NNT). In this study, only four patients needed to undergo the procedure to prevent one death or HF-related hospitalization within the first year. In the world of high-risk structural heart disease, an NNT of four is widely considered an extraordinary clinical achievement.
Chronology of a Clinical Breakthrough
The journey to the TRIC-I-HF results was marked by a rigorous, multicenter design involving 29 high-volume heart-valve centers across Germany. The trial enrolled 360 patients, all of whom presented with symptomatic severe TR.
Baseline Characteristics
The cohort was representative of the complex, geriatric population typically seen in tertiary valve clinics. The mean age of participants was 80.3 years, with 56.4% of the cohort being female. Their baseline condition was dire:
- Severity: 50.8% had severe TR, 34.2% had massive TR, and 10.3% had torrential TR.
- Cardiac Function: The average left ventricular ejection fraction was 54.3%.
- Symptom Burden: Approximately 75% of patients were classified as New York Heart Association (NYHA) class III or IV, indicating significant functional limitation.
- Hospitalization History: 55% of the participants had been hospitalized for heart failure in the 12 months prior to enrollment.
The Procedural Approach
The study protocol randomized participants 2:1 to either receive transcatheter repair or continue with optimized medical therapy. For those in the intervention arm, 98.3% underwent transcatheter edge-to-edge repair (TEER). The procedure utilized commercially available CE-marked systems, specifically the Pascal (65.6%) and the TriClip (33.0%).
The trial design strictly managed crossovers. Patients in the medical therapy group were permitted to "cross over" to the intervention arm only after a severe heart failure decompensation event requiring hospitalization and intravenous diuretic therapy. Of the 48 patients who crossed over, 28 received the valve repair during that index hospitalization, reflecting a pragmatic, real-world application of the technology.
Data Analysis: Why the Trial Succeeded
The success of TRIC-I-HF is largely attributed to the "volume-outcome" relationship. The investigators acknowledged that the tricuspid valve presents a unique anatomical challenge. Unlike the mitral valve, the tricuspid valve has a highly variable anatomy, thin leaflets that are notoriously difficult to grasp, and a complex spatial relationship that complicates echocardiographic imaging.
Hausleiter’s team emphasized that the procedural safety and efficacy observed in the trial were likely tied to the fact that the intervention was performed at 29 specialized centers with highly experienced operators. The procedural safety record was strong, with major adverse events within 30 days occurring in only 5.9% of cases.
Furthermore, the data showed an early divergence in outcomes. The benefit in preventing heart failure hospitalizations became apparent as early as 1.6 years into the trial, and the gap between the two groups continued to widen as time progressed. This suggests that the structural repair of the valve provides a sustained protective effect against the physiological downward spiral of chronic heart failure.
Official Responses and Expert Perspective
The medical community has reacted with profound enthusiasm. Rebecca Hahn, MD, a prominent structural heart specialist at Columbia University Medical Center in New York, served as the discussant for the presentation at the ESC Congress.
"It’s just an incredible result," Hahn remarked during the session. "This is a landmark study that will inform patients and clinicians about the benefit of transcatheter repair therapy. I congratulate the investigators in proving for once and for all that TR reduction can result in a mortality and heart failure hospitalization benefit."
Hahn’s enthusiasm was echoed by other industry experts, who noted that the trial addresses the final frontier of structural heart disease. For years, the lack of hard data left many cardiologists hesitant to refer elderly, frail patients for complex procedures. TRIC-I-HF provides the evidence base required for clinical guidelines to evolve, potentially making TTVR a standard of care for high-risk patients.
Implications for Future Practice
The implications of the TRIC-I-HF findings are multifaceted, touching on clinical decision-making, healthcare economics, and patient quality of life.
Redefining the Standard of Care
For the first time, clinicians have a clear mandate: when a patient presents with symptomatic severe TR, the default should no longer be to wait until they are in end-stage heart failure. The significant reduction in mortality and hospitalizations suggests that early intervention—when anatomy allows—could fundamentally change the trajectory of the disease.
The Importance of Quality of Life
While the primary focus of the trial was on hard endpoints, Dr. Hausleiter was careful to reiterate that quality of life remains a vital consideration. For an 80-year-old patient, the ability to walk to the grocery store or play with grandchildren is often as important as the number of days added to their life.
"Quality of life is important, but also the impact of healthcare hospitalizations and mortality reduction will probably provide us with more arguments to treat more patients with such a therapy," Hausleiter noted during a post-trial press conference. By achieving both, TTVR has positioned itself as an intervention that satisfies both the clinician’s desire for longevity and the patient’s desire for vitality.
Limitations and Future Directions
While the results are overwhelmingly positive, the study authors were transparent about the limitations. Because the trial was conducted in Germany, where the expertise in these specific devices is high and the healthcare infrastructure is robust, the findings may not be immediately generalizable to all regions globally.
Additionally, the researchers are looking forward to future subgroup analyses. Clinicians are eager to understand which patients benefit the most—specifically, identifying whether there is a "sweet spot" in terms of age, comorbid burden, and the specific stage of TR where the procedure is most effective. As the field matures, the focus will likely shift toward refining patient selection criteria to ensure that the resources of high-volume centers are allocated to those who will derive the maximum benefit.
Conclusion
The TRIC-I-HF trial marks the end of the "forgotten valve" era. By demonstrating that transcatheter repair of the tricuspid valve leads to significant improvements in both survival and hospital readmission rates, the trial has fundamentally altered the landscape of valvular heart disease.
As clinicians digest these findings, the focus will turn to implementation. The next phase of this medical evolution will involve scaling this expertise to broader centers, ensuring that the safety and efficacy seen in German high-volume units can be replicated worldwide. For the millions of elderly patients suffering from the debilitating effects of severe tricuspid regurgitation, the message from the ESC Congress is clear: there is finally a path forward, and it leads through the catheter lab.
